US · TNXP · BIOTECHNOLOGY
Tonix Pharmaceuticals Holding Corp. (TNXP) intrinsic value and stock valuation
$2.38as of 2026-11-21 · Mkt cap 191.77M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Tonix Pharmaceuticals Holding Corp. DCF and intrinsic value
InvestorsCraft values TNXP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TNXP’s statements →
Tonix Pharmaceuticals Holding Corp. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.77M | $0.00 | $0.00 |
| Operating income | -$-125.7M | -$-136.7M | -$-118.38M | -$-112.09M | -$-92.31M |
| Net income | -$-124.02M | -$-130.04M | -$-116.66M | -$-110.22M | -$-92.29M |
| EPSd | -$-14.57M | -$-57.54M | -$-63.75M | -$-35.9M | — |
| Operating cash flow | -$-99.84M | -$-60.92M | -$-102M | -$-98.05M | -$-75.56M |
| Capital expenditure | -$-3.37M | -$-120K | -$-7.89M | -$-48.15M | -$-35.31M |
| Free cash flow | -$-103.21M | -$-61.05M | -$-109.9M | -$-146.2M | -$-110.86M |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Total debt | $1.31M | $5.3M | $9.81M | $760K | $960K |
| Net debt | -$-206.33M | -$-93.48M | -$-15.13M | -$-119.47M | -$-177.7M |
| Total equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M |
| Cash and short-term investments | $207.6M | $98.8M | $25M | $120.2M | $178.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.77M | $0.00 | $0.00 |
| Cost of revenue | $8.56M | $7.76M | $4.74M | $0.00 | $0.00 |
| Gross profit | $4.54M | $2.33M | $3.03M | $0.00 | $0.00 |
| Research and development expenses | $44.5M | $40.5M | $86.7M | $81.9M | $68.8M |
| Selling, general and administrative expenses | $85.8M | $40.1M | $34.8M | $30.2M | $23.5M |
| Other expenses | $0.00 | $58.5M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $130.3M | $139M | $121.4M | $112.1M | $92.3M |
| Cost and expenses | $138.8M | $146.8M | $126.2M | $112.1M | $92.3M |
| Interest income | $4.15M | $0.00 | $0.00 | $1.87M | $30K |
| Interest expense | $90K | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.93M | $3.42M | $4.29M | $1.25M | $50K |
| Ebitda | -$-122.01M | -$-74.32M | -$-112.37M | -$-108.97M | -$-92.24M |
| Operating income | -$-125.7M | -$-136.7M | -$-118.38M | -$-112.09M | -$-92.31M |
| Total other income/expenses, net | $1.68M | $6.67M | $1.72M | $1.87M | $30K |
| Income before tax | -$-124.02M | -$-130.04M | -$-116.66M | -$-110.22M | -$-92.29M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-124.02M | -$-130.04M | -$-116.66M | -$-110.22M | -$-92.29M |
| Weighted average shares outstanding | $8.51M | $2.26M | $1.83M | $3.07M | $0.00 |
| Weighted average diluted shares outstanding | $8.51M | $2.26M | $1.83M | $3.07M | $0.00 |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $207.6M | $98.8M | $25M | $120.2M | $178.7M |
| Net receivables | $9.76M | $7.9M | $4.59M | $8.04M | $7.73M |
| Inventory | $6.01M | $8.41M | $14.2M | $0.00 | $0.00 |
| Total current assets | $228.9M | $119M | $47.8M | $130.8M | $189.1M |
| Property, plant and equipment, net | $46M | $42.8M | $94.9M | $94.5M | $51.5M |
| Goodwill and intangible assets | $120K | $120K | $10.7M | $120K | $120K |
| Long-term investments | $2.17M | $900K | $0.00 | $0.00 | $240K |
| Total non-current assets | $48.3M | $43.9M | $106.7M | $94.9M | $51.9M |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Accounts payable | $8.11M | $4.55M | $3.78M | $8.07M | $13.3M |
| Short-term debt | $120K | $270K | $2.62M | $430K | $490K |
| Deferred revenue | $3.42M | $1.82M | $2.98M | $3.27M | $2.83M |
| Total current liabilities | $30.8M | $18.3M | $18.9M | $18.2M | $21.7M |
| Long-term debt | $1.18M | $5.03M | $7.19M | $330K | $470K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.18M | $5.03M | $30.1M | $330K | $470K |
| Capital lease obligations | $1.31M | $630K | $900K | $760K | $960K |
| Total liabilities | $32M | $23.3M | $48.9M | $18.5M | $22.2M |
| Common stock | $10K | $0.00 | $60K | $10K | $500K |
| Retained earnings | -$-854.72M | -$-730.69M | -$-600.66M | -$-470.04M | -$-359.82M |
| Accumulated other comprehensive income (loss) | -$-290K | -$-260K | -$-230K | -$-170K | -$-90K |
| Total equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M |
| Total investments | $2.17M | $900K | $0.00 | $0.00 | $240K |
| Total debt | $1.31M | $5.3M | $9.81M | $760K | $960K |
| Net debt | -$-206.33M | -$-93.48M | -$-15.13M | -$-119.47M | -$-177.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-124.02M | -$-130.04M | -$-116.66M | -$-110.22M | -$-92.29M |
| Depreciation and amortization | $1.93M | $3.42M | $4.29M | $1.25M | $50K |
| Stock-based compensation | $6.02M | $4.78M | $9.28M | $10.9M | $7.9M |
| Change in working capital | $8.54M | $5.78M | -$-40K | -$0.00 | $5.78M |
| Accounts receivable | -$-2.62M | -$-3.68M | $0.00 | $0.00 | $0.00 |
| Inventory | $1.73M | $3.74M | $60K | $0.00 | $0.00 |
| Accounts payable | $2.99M | $930K | -$-3.49M | -$-1.04M | $3.53M |
| Net cash provided by operating activities | -$-99.84M | -$-60.92M | -$-102M | -$-98.05M | -$-75.56M |
| Investments in property, plant and equipment | -$-3.37M | -$-120K | -$-7.89M | -$-48.15M | -$-35.31M |
| Acquisitions, net | $0.00 | $0.00 | -$-22.17M | $0.00 | $0.00 |
| Net cash used for investing activities | -$-4.53M | -$-120K | -$-29.07M | -$-48.15M | -$-35.31M |
| Common stock issued | $237.9M | $140.2M | $18.9M | $94.5M | $212.4M |
| Common stock repurchased | -$-13.76M | $0.00 | -$-13.96M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $214.5M | $134.9M | $36.5M | $87.8M | $212.5M |
| Net change in cash | $110.1M | $73.8M | -$-94.62M | -$-58.43M | $101.6M |
| Cash at end of period | $209.8M | $99.7M | $25.9M | $120.5M | $178.9M |
| Operating cash flow | -$-99.84M | -$-60.92M | -$-102M | -$-98.05M | -$-75.56M |
| Capital expenditure | -$-3.37M | -$-120K | -$-7.89M | -$-48.15M | -$-35.31M |
| Free cash flow | -$-103.21M | -$-61.05M | -$-109.9M | -$-146.2M | -$-110.86M |
Line items
Line items
Line items
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
- CEO
- Seth Lederman
- Employees
- 142
- Beta
- 1.65
Explore
Frequently asked questions
What is the intrinsic value of Tonix Pharmaceuticals Holding Corp. (TNXP)?
Tonix Pharmaceuticals Holding Corp. (TNXP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TNXP undervalued?
TNXP trades at a price of $2.38 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.